Moderna (MRNA) – Research Analysts’ Recent Ratings Updates

Several analysts have recently updated their ratings and price targets for Moderna (NASDAQ: MRNA):

• 2/18/2025 – Moderna had its “sector perform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $40.00 price target on the stock.
• 2/18/2025 – Moderna was downgraded by analysts at Barclays PLC from an “overweight” rating to an “equal weight” rating. They now have a $45.00 price target on the stock, down previously from $111.00.
• 2/11/2025 – Moderna had its price target lowered by analysts at Bank of America Co. from $41.00 to $34.00. They now have an “underperform” rating on the stock.
• 1/29/2025 – Moderna was downgraded by analysts at The Goldman Sachs Group, Inc. from a “buy” rating to a “neutral” rating. They now have a $51.00 price target on the stock, down previously from $99.00.
• 1/28/2025 – Moderna had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $112.00 to $99.00. They now have a “buy” rating on the stock.
• 1/27/2025 – Moderna had its price target lowered by analysts at Evercore ISI from $60.00 to $50.00. They now have an “in-line” rating on the stock.
• 1/16/2025 – Moderna had its price target lowered by analysts at Leerink Partners from $31.00 to $27.00. They now have an “underweight” rating on the stock.
• 1/16/2025 – Moderna had its price target raised by analysts at Berenberg Bank from $33.00 to $42.00. They now have a “hold” rating on the stock.
• 1/15/2025 – Moderna had its price target lowered by analysts at Morgan Stanley from $70.00 to $38.00. They now have an “equal weight” rating on the stock.
• 1/8/2025 – Moderna had its price target lowered by analysts at UBS Group AG from $108.00 to $96.00. They now have a “buy” rating on the stock.

Moderna Trading Up 8.3 %

NASDAQ MRNA opened at $35.72 on Wednesday. Moderna, Inc. has a 12-month low of $29.25 and a 12-month high of $170.47. The company has a fifty day simple moving average of $38.61 and a two-hundred day simple moving average of $53.82. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The stock has a market cap of $13.75 billion, a P/E ratio of -6.14 and a beta of 1.59.

Insider Buying and Selling

In related news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the sale, the insider now owns 19,717 shares of the company’s stock, valued at $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold 2,664 shares of company stock worth $115,210 in the last 90 days. Insiders own 15.70% of the company’s stock.

Hedge Funds Weigh In On Moderna

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Norges Bank acquired a new position in shares of Moderna during the 4th quarter worth about $163,833,000. Voloridge Investment Management LLC increased its stake in Moderna by 335.6% during the 4th quarter. Voloridge Investment Management LLC now owns 2,590,831 shares of the company’s stock worth $107,727,000 after buying an additional 1,996,003 shares in the last quarter. State Street Corp raised its holdings in shares of Moderna by 12.1% during the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after acquiring an additional 1,823,276 shares during the last quarter. FMR LLC lifted its position in shares of Moderna by 7.4% in the fourth quarter. FMR LLC now owns 18,664,634 shares of the company’s stock valued at $776,075,000 after acquiring an additional 1,282,469 shares in the last quarter. Finally, Pictet Asset Management Holding SA lifted its holdings in Moderna by 170.5% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,766,398 shares of the company’s stock valued at $73,447,000 after purchasing an additional 1,113,455 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.